Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 11;10(4):322. doi: 10.1038/s41419-019-1555-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Ovarian cancer cells were treated with different concentrations of cisplatin (CDDP, 0–32 μM) or paclitaxel (PAC, 0–64 μM), or combined with 2 μM SC66 for 48 h. Each combination was tested with n = 5 replicates. After 48 h of treatment, cell viability was assessed by MTT assays. All experiments were performed in triplicate. The IC₅₀ values of each agent in single or combination treatments and CI values of the SC66 + CDDP or SC66 + PAC combinations. P-value between the IC₅₀ values of single vs. combination treatment. b Ovarian cancer cells were treated for 24 h with 2 μM SC66 alone or with the addition of anticancer drugs (10 μM) indicated. The percentage of apoptotic cells was determined by Annexin V and PI staining. Mean ± SD for three independent experiments are shown. *P < 0.05 and **P < 0.005, SC66 + CDDP vs. CDDP or SC66 + PAC vs. PAC. c Colony formation assay. Ovarian cancer cells were treated with 2 μM SC66 with or without the addition of the anticancer drugs (10 μM) indicated for 14 d (A2780 and A2780CP70) or 21 d (ES-2 and ES-2CP). After treatment, cells were stained with crystal violet. Mean ± SD for three independent experiments are shown. *P < 0.05 and **P < 0.005, SC66 + CDDP vs. CDDP or SC66 + PAC vs. PAC

Fig. 3 — a Ovarian cancer cells were treated with different concentrations of cisplatin (CDDP, 0–32 μM) or paclitaxel (PAC, 0–64 μM), or combined with 2 μM SC66 for 48 h. Each combination was tested with n = 5 replicates. After 48 h of treatment, cell viability was assessed by MTT assays. All experiments were performed in triplicate. The IC₅₀ values of each agent in single or combination treatments and CI values of the SC66 + CDDP or SC66 + PAC combinations. P-value between the IC₅₀ values of single vs. combination treatment. b Ovarian cancer cells were treated for 24 h with 2 μM SC66 alone or with the addition of anticancer drugs (10 μM) indicated. The percentage of apoptotic cells was determined by Annexin V and PI staining. Mean ± SD for three independent experiments are shown. *P < 0.05 and **P < 0.005, SC66 + CDDP vs. CDDP or SC66 + PAC vs. PAC. c Colony formation assay. Ovarian cancer cells were treated with 2 μM SC66 with or without the addition of the anticancer drugs (10 μM) indicated for 14 d (A2780 and A2780CP70) or 21 d (ES-2 and ES-2CP). After treatment, cells were stained with crystal violet. Mean ± SD for three independent experiments are shown. *P < 0.05 and **P < 0.005, SC66 + CDDP vs. CDDP or SC66 + PAC vs. PAC